Insulin Delivery System Companies Strategic Expansion Initiatives, Revenue Diversification, Strategic Joint Ventures, Licensing and Monetization, Peer Comparison Analysis, Leadership and Governance

Insulin Delivery System Market Companies and their Innovations

The global insulin delivery system market size is calculated at US$ 17.77 in 2024, grew to US$ 19.18 billion in 2025, and is projected to reach around US$ 38.09 billion by 2034. The market is expanding at a CAGR of 7.92% between 2024 and 2034.

Top Companies in the Insulin Delivery System are:

• Novo Nordisk A/S
• Medtronic
• B. Braun SE
• Insulet Corporation
• Sanofi
• Owen Mumford Ltd.
• Eli Lilly and Company
• BD (Becton, Dickinson, and Company)
• Ypsomed AG
• Tandem Diabetes Care, Inc.

Latest Announcements by Industry Leaders

In November 2024, Doctors Without Borders (MSF) asked pharmaceutical companies Eli Lilly, Novo Nordisk, Sanofi, and all insulin manufacturers to act quickly to improve access to diabetes treatment in low- and middle-income nations by making insulin* pen injection devices available at a price of US$1 (R17.81) per pen in advance of World Diabetes Day.

Recent Developments in the Insulin Delivery System Market

• In August 2024, Abbott and Medtronic announced a unique global partnership to work together on an integrated continuous glucose monitoring (CGM) system that will connect to Medtronic's automated insulin delivery (AID) and smart insulin pen systems. The system will be built on Abbott's most cutting-edge, industry-leading FreeStyle Libre technology.
• In August 2024, the U.S. Food and Drug Administration (FDA) approved the SimpleraTM continuous glucose monitor (CGM), the company's first disposable, all-in-one CGM that is half the size of earlier Medtronic CGMs. Medtronic plc is a global pioneer in healthcare technology.
• In August 2024, as the first and only AID system FDA-approved for the management of both type 1 and type 2 diabetes, Insulet Corporation announced that its revolutionary Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now recommended for use by individuals with type 2 diabetes (those aged 18 and older) in the United States.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com